Treatment of older patients with head and neck cancer: a review
NA VanderWalde, M Fleming, J Weiss… - The oncologist, 2013 - academic.oup.com
Learning Objectives Compare survival and toxicity outcomes of older patients with head and
neck cancer with those of their younger cohorts. Describe the role played by comorbidity …
neck cancer with those of their younger cohorts. Describe the role played by comorbidity …
Squamous cell carcinoma of the head and neck in the elderly
J Gugić, P Strojan - Reports of Practical Oncology and …, 2013 - journals.viamedica.pl
The incidence of head and neck squamous cell carcinoma (HNSCC) peaks between the fifth
and seventh decades of life. With prolongation of life expectancy, however, the proportion of …
and seventh decades of life. With prolongation of life expectancy, however, the proportion of …
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology …
A Argiris, M Ghebremichael, J Gilbert… - Journal of Clinical …, 2013 - ascopubs.org
Purpose We hypothesized that the addition of gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in …
(EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in …
Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management …
F Peyrade, D Cupissol, L Geoffrois, F Rolland, C Borel… - Oral oncology, 2013 - Elsevier
OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy
RJ Maggiore, EK Curran, ME Witt, DJ Haraf… - Journal of geriatric …, 2013 - Elsevier
Objectives Chemoradiation therapy (CRT) remains a potentially curative treatment in
patients with locally advanced head/neck cancer (LA-HNC). However, survival and other …
patients with locally advanced head/neck cancer (LA-HNC). However, survival and other …
Absence of effect of SLC22A2 genotype on cisplatin‐induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5‐fluorouracil: report of results …
Y Hinai, S Motoyama, T Niioka… - Journal of clinical …, 2013 - Wiley Online Library
What is known and objective Cancer patients treated with cisplatin chemotherapy frequently
experience drug‐induced nephrotoxicity. Clinical studies using a single chemotherapeutic …
experience drug‐induced nephrotoxicity. Clinical studies using a single chemotherapeutic …
[PDF][PDF] Multidisciplinary approach of head and neck cancer in the elderly: an update
G Mountzios, A Soultati, K Syrigos - Head Neck Oncol, 2013 - researchgate.net
Squamous-cell carcinoma of the head and neck (SCCHN) represents the sixth most
common malignancy and accounts for approximately 6% of new cancer cases annually …
common malignancy and accounts for approximately 6% of new cancer cases annually …
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck
SW Loo, K Geropantas… - European Journal of …, 2013 - Wiley Online Library
LOO SW, GEROPANTAS K., TASIGIANNOPOULOS Z., MARTIN C. & ROQUES TW (2013)
European Journal of Cancer Care22, 32–40 Feasibility and tolerance of sequential …
European Journal of Cancer Care22, 32–40 Feasibility and tolerance of sequential …
Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population
IA Reveles - 2013 - repositories.lib.utexas.edu
Introduction: Current treatment recommendations for advanced SCCHN include the use of
combined modality therapy (eg, radiation plus chemotherapy/biologic therapy). The new …
combined modality therapy (eg, radiation plus chemotherapy/biologic therapy). The new …
抗がん剤の有害事象対策
松浦一登 - 日本耳鼻咽喉科学会会報, 2013 - jstage.jst.go.jp
抄録 がん治療の究極の夢は 「薬」 で病が治ることである. 効果を得るために治療強度を増すことは
しばしば行われるが, 副作用も強くなるというジレンマがある. 近年, 分子標的薬剤など新しい創薬が …
しばしば行われるが, 副作用も強くなるというジレンマがある. 近年, 分子標的薬剤など新しい創薬が …